{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:42:24Z","timestamp":1790527344019,"version":"4.1.0"},"reference-count":98,"publisher":"American Psychiatric Association Publishing","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PS"],"published-print":{"date-parts":[[2001,11]]},"DOI":"10.1176\/appi.ps.52.11.1469","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:03:29Z","timestamp":1034359409000},"page":"1469-1478","source":"Crossref","is-referenced-by-count":82,"title":["Can Recovery From Depression Be Achieved?"],"prefix":"10.1176","volume":"52","author":[{"given":"Richard C.","family":"Shelton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Tomarken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R52111111","doi-asserted-by":"crossref","unstructured":"Robins LN, Helzer JE, Weissman MM, et al: Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry 41:949-958, 1984","DOI":"10.1001\/archpsyc.1984.01790210031005"},{"key":"R52111112","doi-asserted-by":"crossref","unstructured":"Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry 51:8-19, 1994","DOI":"10.1001\/archpsyc.1994.03950010008002"},{"key":"R52111113","doi-asserted-by":"crossref","unstructured":"Zis AP, Goodwin FK: Major affective disorder as a recurrent illness: a critical review. Archives of General Psychiatry 36:835-839, 1979","DOI":"10.1001\/archpsyc.1979.01780080009002"},{"key":"R52111114","doi-asserted-by":"crossref","unstructured":"Consensus Development Panel: NIMH\/NIH consensus development conference statement on mood disorders: pharmacological prevention of recurrences. American Journal of Psychiatry 142:469-476, 1985","DOI":"10.1176\/ajp.142.4.469"},{"key":"R52111115","doi-asserted-by":"crossref","unstructured":"Klerman GL, Weissman MM: The course, morbidity, and costs of depression. Archives of General Psychiatry 49:831-834, 1992","DOI":"10.1001\/archpsyc.1992.01820100075013"},{"key":"R52111116","doi-asserted-by":"crossref","unstructured":"Keller MB, Lavori PW, Mueller TI, et al: Time to recovery, chronicity, and levels of psychopathology in major depression. Archives of General Psychiatry 49:809-816, 1992","DOI":"10.1001\/archpsyc.1992.01820100053010"},{"key":"R52111117","doi-asserted-by":"crossref","unstructured":"Hirschfeld RM, Montgomery SA, Keller MB, et al: Social functioning in depression: a review. Journal of Clinical Psychiatry 61:268-275, 2000","DOI":"10.4088\/JCP.v61n0405"},{"key":"R52111119","doi-asserted-by":"crossref","unstructured":"Lopez AD, Murray CC: The global burden of disease, 1990-2020. Nature Medicine 4:1241-1243, 1998","DOI":"10.1038\/3218"},{"key":"R521111110","doi-asserted-by":"crossref","unstructured":"Ustin TB: The global burden of mental disorders. American Journal of Public Health 89:1315-1318, 1999","DOI":"10.2105\/AJPH.89.9.1315"},{"key":"R521111111","doi-asserted-by":"crossref","unstructured":"Salomone DA, Keller MB, Leon AC, et al: Recovery from major depression: a 10-year prospective follow-up across multiple episodes. Archives of General Psychiatry 54:1001-1006, 1997","DOI":"10.1001\/archpsyc.1997.01830230033005"},{"key":"R521111112","doi-asserted-by":"crossref","unstructured":"Frank E, Prien RF, Jarrett RB, et al: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Archives of General Psychiatry 48:851-855, 1991","DOI":"10.1001\/archpsyc.1991.01810330075011"},{"key":"R521111113","doi-asserted-by":"crossref","unstructured":"Healey D, Healey H: The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of well being? Journal of Affective Disorders 51:313-322, 1998","DOI":"10.1016\/S0165-0327(98)00227-4"},{"key":"R521111114","doi-asserted-by":"crossref","unstructured":"Watson D, Weber K, Assenheimer JS, et al: Testing a tripartite model: I. evaluating the convergent and discriminant validity of anxiety and depression symptom subscales. Journal of Abnormal Psychology 1:3-14, 1995","DOI":"10.1037\/\/0021-843X.104.1.3"},{"key":"R521111115","doi-asserted-by":"crossref","unstructured":"Watson D, Clark LA, Weber K, et al: Testing a tripartite model: II. exploring the symptom structure of anxiety and depression in student, adult, and patient samples. Journal of Abnormal Psychology 104:15-25, 1995","DOI":"10.1037\/\/0021-843X.104.1.15"},{"key":"R521111116","doi-asserted-by":"crossref","unstructured":"Brown TA, Chorpita BF, Barlow DH: Structural relationships among dimensions of the DSM-IV anxiety and mood disorders and dimensions of negative affect, positive affect, and autonomic arousal. Journal of Abnormal Psychology 107:179-192, 1998","DOI":"10.1037\/\/0021-843X.107.2.179"},{"key":"R521111117","doi-asserted-by":"crossref","unstructured":"Lang PJ, Bradley MM, Cuthbert BN: Emotion, motivation, and anxiety: brain mechanisms and psychophysiology. Biological Psychiatry 44:1248-1263, 1998","DOI":"10.1016\/S0006-3223(98)00275-3"},{"key":"R521111118","doi-asserted-by":"crossref","unstructured":"Lang PJ, Davis M, Lehman A: Fear and anxiety: animal models and human cognitive psychophysiology. Journal of Affective Disorders 61:137-159, 2000","DOI":"10.1016\/S0165-0327(00)00343-8"},{"key":"R521111119","doi-asserted-by":"crossref","unstructured":"Clark LA, Watson D: Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. Journal of Abnormal Psychology 100:316-336, 1991","DOI":"10.1037\/\/0021-843X.100.3.316"},{"key":"R521111120","doi-asserted-by":"crossref","unstructured":"Mineka S, Watson D, Clark LA: Comorbidity of anxiety and unipolar mood disorders. Annual Review of Psychology 49:377-412, 1998","DOI":"10.1146\/annurev.psych.49.1.377"},{"key":"R521111121","unstructured":"Shelton RC, Brown L: Mechanisms of action in the treatment of anxiety. Journal of Clinical Psychiatry 62(suppl 12):10-15, 2000"},{"key":"R521111122","doi-asserted-by":"crossref","unstructured":"Kendler KS, Neale MC, Kessler RC, et al: Major depression and generalized anxiety disorder: same genes, (partly) different environments? Archives of General Psychiatry 49:1622, 1992","DOI":"10.1001\/archpsyc.1992.01820090044008"},{"key":"R521111123","unstructured":"Neale MC, Kendler KS: Models of comorbidity for multifactorial disorders. American Journal of Human Genetics 57:935-953, 1995"},{"key":"R521111124","doi-asserted-by":"crossref","unstructured":"Kendler KS: Major depression and generalised anxiety disorder: same genes, (partly) different environments\u2014revisited. British Journal of Psychiatry 30(suppl):68-75, 1996","DOI":"10.1192\/S0007125000298437"},{"key":"R521111125","doi-asserted-by":"crossref","unstructured":"Kendler KS, Davis CG, Kessler RC: The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. British Journal of Psychiatry 170:541-548, 1997","DOI":"10.1192\/bjp.170.6.541"},{"key":"R521111126","doi-asserted-by":"crossref","unstructured":"Hewitt JK, Silberg JL, Rutter M, et al: Genetics and developmental psychopathology: I. phenotypic assessment in the Virginia Twin Study of Adolescent Behavioral Development. Journal of Child Psychology and Psychiatry and Allied Disciplines 38:943-963, 1997","DOI":"10.1111\/j.1469-7610.1997.tb01613.x"},{"key":"R521111127","doi-asserted-by":"crossref","unstructured":"Kendler KS, Karkowski LM, Prescott CA: Stressful life events and major depression: risk period, long-term contextual threat, and diagnostic specificity. Journal of Nervous and Mental Disease 186:661-669, 1998","DOI":"10.1097\/00005053-199811000-00001"},{"key":"R521111128","doi-asserted-by":"crossref","unstructured":"Boyer P: Do anxiety and depression have a common pathophysiological mechanism? Acta Psychiatrica Scandinavica Supplement 406:24-29, 2000","DOI":"10.1111\/j.0065-1591.2000.acp29[dash]04.x"},{"key":"R521111129","doi-asserted-by":"crossref","unstructured":"Watson D, Tellegen A: Toward a consensual structure of mood. Psychology Bulletin 98:219-235, 1985","DOI":"10.1037\/\/0033-2909.98.2.219"},{"key":"R521111130","unstructured":"Petty F, Davis LL, Kabel D, et al: Serotonin dysfunction disorders: a behavioral neurochemistry perspective. Journal of Clinical Psychiatry 57(suppl 8):11-16, 1996"},{"key":"R521111131","doi-asserted-by":"crossref","unstructured":"Berendsen HH: Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmacology and Therapeutics 66:17-37, 1995","DOI":"10.1016\/0163-7258(94)00075-E"},{"key":"R521111132","doi-asserted-by":"crossref","unstructured":"Petty F, Kramer GL, Wu J: Serotonergic modulation of learned helplessness. Annals of the New York Academy of Sciences 821:538-541, 1997","DOI":"10.1111\/j.1749-6632.1997.tb48324.x"},{"key":"R521111133","doi-asserted-by":"crossref","unstructured":"Silverstone PH, Rue JE, Franklin M, et al: The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal, and MHPG measurements in human volunteers. International Clinical Psychopharmacology 9:173-178, 1994","DOI":"10.1097\/00004850-199409000-00005"},{"key":"R521111134","doi-asserted-by":"crossref","unstructured":"Cervo L, Mocaer E, Bertaglia A, et al: Roles of 5-HT1A receptors in the dorsal raphe and dorsal hippocampus in anxiety assessed by the behavioral effects of 8-OH-DPAT and S 15535 in a modified Geller-Seifter conflict model. Neuropharmacology 39:1037-1043, 2000","DOI":"10.1016\/S0028-3908(99)00189-6"},{"key":"R521111135","unstructured":"Gorman JM, Kent JM: SSRIs and SMRIs: broad spectrum of efficacy beyond major depression. Journal of Clinical Psychiatry 60(suppl 4):33-38, 1999"},{"key":"R521111136","doi-asserted-by":"crossref","unstructured":"Van Praag HM, Kahn R, Asnis GM, et al: Therapeutic indications for serotonin-potentiating compounds: a hypothesis. Biological Psychiatry 22:205-212, 1987","DOI":"10.1016\/0006-3223(87)90232-0"},{"key":"R521111137","doi-asserted-by":"crossref","unstructured":"Knutson B, Wolkowitz OM, Cole SW, et al: Selective alteration of personality and social behavior by serotonergic innervation. American Journal of Psychiatry 155:137-145, 1997","DOI":"10.1176\/ajp.155.3.373"},{"key":"R521111138","doi-asserted-by":"crossref","unstructured":"Bodkin JA, Lasser RA, Wines JD Jr, et al: Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. Journal of Clinical Psychiatry 58:137-145, 1997","DOI":"10.4088\/JCP.v58n0401"},{"key":"R521111139","doi-asserted-by":"crossref","unstructured":"Katz MM, Koslow SH, Maas JW, et al: The timing, specificity, and clinical prediction of tricyclic drug effects in depression. Psychological Medicine 17:297-309, 1987","DOI":"10.1017\/S0033291700024831"},{"key":"R521111140","doi-asserted-by":"crossref","unstructured":"Depue RA, Spoont MR: Conceptualizing a serotonin trait: a behavioral dimension of constraint. Annals of the New York Academy of Sciences 487:47-62, 1986","DOI":"10.1111\/j.1749-6632.1986.tb27885.x"},{"key":"R521111141","doi-asserted-by":"crossref","unstructured":"Zald DH, Depue RA: Serotonergic functioning correlates with positive and negative affect in psychiatrically healthy males. Personality and Individual Differences 30:71-86, 2001","DOI":"10.1016\/S0191-8869(00)00011-8"},{"key":"R521111142","doi-asserted-by":"crossref","unstructured":"Charney DS, Redmond DE Jr: Neurobiological mechanisms in human anxiety: evidence supporting central noradrenergic hyperactivity. Neuropharmacology 22:1531-1536, 1983","DOI":"10.1016\/0028-3908(83)90122-3"},{"key":"R521111143","doi-asserted-by":"crossref","unstructured":"Bremner JD, Krystal JH, Southwick SM, et al: Noradrenergic mechanisms in stress and anxiety: I. preclinical studies. Synapse 23:28-38, 1996","DOI":"10.1002\/(SICI)1098-2396(199605)23:1<28::AID-SYN4>3.0.CO;2-J"},{"key":"R521111144","doi-asserted-by":"crossref","unstructured":"Bremner JD, Krystal JH, Southwick SM, et al: Noradrenergic mechanisms in stress and anxiety: II. clinical studies. Synapse 23:39-51, 1996","DOI":"10.1002\/(SICI)1098-2396(199605)23:1<39::AID-SYN5>3.3.CO;2-Y"},{"key":"R521111145","doi-asserted-by":"crossref","unstructured":"Sullivan GM, Coplan JD, Kent JM, et al: The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biological Psychiatry 46:1205-1218, 1999","DOI":"10.1016\/S0006-3223(99)00246-2"},{"key":"R521111146","doi-asserted-by":"crossref","unstructured":"Tanaka M, Yoshida M, Emoto H, et al: Noradrenaline systems in the hypothalamus, amygdala, and locus coeruleus are involved in the provocation of anxiety: basic studies. European Journal of Pharmacology 405:397-406, 2000","DOI":"10.1016\/S0014-2999(00)00569-0"},{"key":"R521111147","unstructured":"Rosenbaum JF: Treatment of outpatients with desipramine. Journal of Clinical Psychiatry 45:17-22, 1984"},{"key":"R521111148","doi-asserted-by":"crossref","unstructured":"Kalus O, Asnis GM, Rubinson E, et al: Desipramine treatment in panic disorder. Journal of Affective Disorders 21:239-244, 1991","DOI":"10.1016\/0165-0327(91)90003-B"},{"key":"R521111149","unstructured":"Pohl R, Yeragani VK, Balon R, et al: The jitteriness syndrome in panic disorder patients treated with antidepressants. Journal of Clinical Psychiatry 2:72-73, 1989"},{"key":"R521111150","doi-asserted-by":"crossref","unstructured":"McLeod DR, Hoehn-Saric R, Porges SW, et al: Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 20:615-621, 2000","DOI":"10.1097\/00004714-200012000-00006"},{"key":"R521111151","doi-asserted-by":"crossref","unstructured":"Depue RA, Collins P: Neurobiology and the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behavioral and Brain Sciences 22:491-569, 1999","DOI":"10.1017\/S0140525X99002046"},{"key":"R521111152","doi-asserted-by":"crossref","unstructured":"Depue RA, Luciana M, Arbisi P, et al: Dopamine and the structure of personality: relation of agonist-induced dopamine activity to positive emotionality. Journal of Personality and Social Psychology 67:485-498, 1994","DOI":"10.1037\/\/0022-3514.67.3.485"},{"key":"R521111153","doi-asserted-by":"crossref","unstructured":"Stahl SM: Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. Journal of Clinical Psychiatry 59(suppl 18):23-29, 1998","DOI":"10.4088\/JCP.v59n0107a"},{"key":"R521111154","doi-asserted-by":"crossref","unstructured":"Reith ME, Li MY, Yan QS: Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berlin) 134:309-317, 1997","DOI":"10.1007\/s002130050454"},{"key":"R521111155","doi-asserted-by":"crossref","unstructured":"Hajnal A, Mark GP, Rada PV, et al: Norepinephrine microinjections in the hypothalamic paraventricular nucleus increase extracellular dopamine and decrease acetylcholine in the nucleus accumbens: relevance to feeding reinforcement. Journal of Neurochemistry 68:667-674, 1997","DOI":"10.1046\/j.1471-4159.1997.68020667.x"},{"key":"R521111156","doi-asserted-by":"crossref","unstructured":"Pacholcyzk T, Blakely RD, Amara SG: Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350-354, 1991","DOI":"10.1038\/350350a0"},{"key":"R521111157","doi-asserted-by":"crossref","unstructured":"Karson CN: Oculomotor signs in a psychiatric population: a preliminary report. American Journal of Psychiatry 136:1057-1060, 1979","DOI":"10.1176\/ajp.136.8.1057"},{"key":"R521111158","doi-asserted-by":"crossref","unstructured":"Aston-Jones G, Rajkowski J, Cohen J: Role of locus coeruleus in attention and behavioral flexibility. Biological Psychiatry 46:1309-1320, 1999","DOI":"10.1016\/S0006-3223(99)00140-7"},{"key":"R521111159","doi-asserted-by":"crossref","unstructured":"De Deurwaerdere P, Spampinato U: Role of serotonin2A and serotonin2B\/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. Journal of Neurochemistry 73:1033-1042, 1999","DOI":"10.1046\/j.1471-4159.1999.0731033.x"},{"key":"R521111160","doi-asserted-by":"crossref","unstructured":"Lucas G, Spampinato U: Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. Journal of Neurochemistry 74:693-701, 2000","DOI":"10.1046\/j.1471-4159.2000.740693.x"},{"key":"R521111161","doi-asserted-by":"crossref","unstructured":"Lucas G, De Deurwaerdere P, Caccia S, et al: The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT2A and 5-HT2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39:1053-1063, 2000","DOI":"10.1016\/S0028-3908(99)00193-8"},{"key":"R521111162","doi-asserted-by":"crossref","unstructured":"Prisco S, Esposito E: Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. British Journal of Pharmacology 116:1923-1931, 1995","DOI":"10.1111\/j.1476-5381.1995.tb16684.x"},{"key":"R521111163","doi-asserted-by":"crossref","unstructured":"Ichikawa J, Kuroki T, Meltzer HY: Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens. European Journal of Pharmacology 350:159-164, 1998","DOI":"10.1016\/S0014-2999(98)00247-7"},{"key":"R521111164","doi-asserted-by":"crossref","unstructured":"Katz RJ, Carroll BJ: Intracranial reward after Lilly 110140 (fluoxetine HCl): evidence for an inhibitory role for serotonin. Psychopharmacology 1:189-193, 1977","DOI":"10.1007\/BF00431739"},{"key":"R521111165","doi-asserted-by":"crossref","unstructured":"Cazala P: Effects of Lilly 110140 (fluoxetine) on self-stimulation behavior in the dorsal and ventral regions of the lateral hypothalamus in the mouse. Psychopharmacology 71:143-146, 1980","DOI":"10.1007\/BF00434402"},{"key":"R521111166","doi-asserted-by":"crossref","unstructured":"Lee K, Kornetsky C: Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation. Pharmacology, Biochemistry, and Behavior 60:539-544, 1998","DOI":"10.1016\/S0091-3057(98)00020-3"},{"key":"R521111169","doi-asserted-by":"crossref","unstructured":"Stahl SM: The 7 habits of highly effective psychopharmacologists: II. begin with the end in mind. Journal of Clinical Psychiatry 61:327-328, 2000","DOI":"10.4088\/JCP.v61n0501"},{"key":"R521111170","doi-asserted-by":"crossref","unstructured":"Roose SP, Glassman AH, Attia E, et al: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 151:1735-1739, 1994","DOI":"10.1176\/ajp.151.12.1735"},{"key":"R521111171","doi-asserted-by":"crossref","unstructured":"Perry PJ: Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Journal of Affective Disorders 39:1-6, 1996","DOI":"10.1016\/0165-0327(96)00014-6"},{"key":"R521111172","doi-asserted-by":"crossref","unstructured":"Stahl SM: Are two antidepressant mechanisms better than one? Journal of Clinical Psychiatry 58:339-340, 1997","DOI":"10.4088\/JCP.v58n0801"},{"key":"R521111173","doi-asserted-by":"crossref","unstructured":"Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 178:234-241, 2001","DOI":"10.1192\/bjp.178.3.234"},{"key":"R521111174","doi-asserted-by":"crossref","unstructured":"Shader RI, Fogelman SM, Greenblatt DJ: Newer antidepressants: hypotheses and evidence. Journal of Clinical Psychopharmacology 17:1-3, 1997","DOI":"10.1097\/00004714-199702000-00001"},{"key":"R521111175","doi-asserted-by":"crossref","unstructured":"Nelson JC, Mazure CM, Bowers MB Jr, et al: A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry 48:303-307, 1991","DOI":"10.1001\/archpsyc.1991.01810280019002"},{"key":"R521111176","doi-asserted-by":"crossref","unstructured":"Sprenger D: Buspirone augmentation of a selective serotonin reuptake inhibitor: efficacy in two depressed patients with comorbid anxiety and type I alcohol dependence. Journal of Clinical Psychopharmacology 17:425-426, 1997","DOI":"10.1097\/00004714-199710000-00014"},{"key":"R521111177","doi-asserted-by":"crossref","unstructured":"Marshall RD, Liebowitz MR: Paroxetine\/bupropion combination treatment for refractory depression. Journal of Clinical Psychopharmacology 16:80-81, 1996","DOI":"10.1097\/00004714-199602000-00016"},{"key":"R521111178","doi-asserted-by":"crossref","unstructured":"Quitkin FM, Stewart JW, McGrath PJ, et al: Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. British Journal of Psychiatry Supplement 21:30-34, 1993","DOI":"10.1192\/S0007125000292465"},{"key":"R521111179","doi-asserted-by":"crossref","unstructured":"Stewart JW, McGrath PJ, Rabkin JG, et al: Atypical depression: a valid clinical entity? Psychiatric Clinics of North America 16:479-495, 1993","DOI":"10.1016\/S0193-953X(18)30161-8"},{"key":"R521111180","doi-asserted-by":"crossref","unstructured":"Cohen LJ: Rational drug use in the treatment of depression. Pharmacotherapy 17:45-61, 1997","DOI":"10.1002\/j.1875-9114.1997.tb03677.x"},{"key":"R521111181","doi-asserted-by":"crossref","unstructured":"Strata P, Bolino F, Cupillari M, et al: A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. International Clinical Psychopharmacology 6:193-196, 1991","DOI":"10.1097\/00004850-199100630-00007"},{"key":"R521111182","doi-asserted-by":"crossref","unstructured":"Pande AC, Birkett M, Fechner-Bates S, et al: Fluoxetine versus phenelzine in atypical depression. Biological Psychiatry 40:1017-1020, 1996","DOI":"10.1016\/0006-3223(95)00628-1"},{"key":"R521111183","doi-asserted-by":"crossref","unstructured":"McGrath PJ, Stewart JW, Janal MN, et al: A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. American Journal of Psychiatry 157:344-350, 2000","DOI":"10.1176\/appi.ajp.157.3.344"},{"key":"R521111184","doi-asserted-by":"crossref","unstructured":"McGrath PJ, Stewart JW, Quitkin FM, et al: Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. Journal of Clinical Psychopharmacology 14:347-352, 1994","DOI":"10.1097\/00004714-199410000-00011"},{"key":"R521111185","doi-asserted-by":"crossref","unstructured":"Janicak PG, Martin B: Strategies for treatment-resistant depression. Clinical Cornerstone 1:58-71, 1999","DOI":"10.1016\/S1098-3597(99)90024-8"},{"key":"R521111186","unstructured":"Shelton RC: Treatment options for refractory depression. Journal of Clinical Psychi-atry 60(suppl 4):57-63, 1999"},{"key":"R521111187","unstructured":"Nelson JC: Augmentation strategies in depression 2000. Journal of Clinical Psychiatry 61(suppl 2):13-19, 2000"},{"key":"R521111188","unstructured":"Fava M: New approaches to the treatment of refractory depression. Journal of Clinical Psychiatry 61(suppl 1):26-32, 2000"},{"key":"R521111189","unstructured":"Liebowitz MR: Depression with anxiety and atypical depression. Journal of Clinical Psychiatry 54(suppl):10-14, 1993"},{"key":"R521111190","doi-asserted-by":"crossref","unstructured":"Carli M, Afkhami-Dastjerdian S, Reader TA: Effects of a chronic lithium treatment on cortical serotonin uptake sites and 5-HT1A receptors. Neurochemical Research 22:427-435, 1997","DOI":"10.1023\/A:1027355626355"},{"key":"R521111191","doi-asserted-by":"crossref","unstructured":"Massot O, Rousselle JC, Fillion MP, et al:5-HT1B receptors: a novel target for lithium: possible involvement in mood disorders. Neuropsychopharmacology 21:530-541, 1999","DOI":"10.1016\/S0893-133X(99)00042-1"},{"key":"R521111192","doi-asserted-by":"crossref","unstructured":"Haddjeri N, Szabo ST, de Montigny C, et al: Increased tonic activation of rat forebrain 5-HT1A receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology 22:346-356, 2000","DOI":"10.1016\/S0893-133X(99)00138-4"},{"key":"R521111193","doi-asserted-by":"crossref","unstructured":"Bleier P, Bergeron R, de Montigny C: Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 16:333-338, 1997","DOI":"10.1016\/S0893-133X(96)00242-4"},{"key":"R521111194","unstructured":"Nelson JC: Augmentation strategies with serotonergic-noradrenergic combinations. Journal of Clinical Psychiatry 59(suppl 5):65-68, 1998"},{"key":"R521111195","doi-asserted-by":"crossref","unstructured":"Fatemi SH, Emamian ES, Kist DA: Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Annals of Pharmacotherapy 33:701-703, 1999","DOI":"10.1345\/aph.18249"},{"key":"R521111196","unstructured":"Nierenberg AA, Dougherty D, Rosenbaum JF: Dopaminergic agents and stimulants as antidepressant augmentation strategies. Journal of Clinical Psychiatry 59(suppl 5):60-63, 1998"},{"key":"R521111197","doi-asserted-by":"crossref","unstructured":"Shelton R, Tollefson GD, Tohen M, et al: A novel augmentation strategy for treatment-resistant major depression. American Journal of Psychiatry 158:131-134, 2001","DOI":"10.1176\/appi.ajp.158.1.131"},{"key":"R521111198","doi-asserted-by":"crossref","unstructured":"Ostroff RB, Nelson JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Journal of Clinical Psychiatry 60:256-259, 1999","DOI":"10.4088\/JCP.v60n0410"},{"key":"R521111199","doi-asserted-by":"crossref","unstructured":"Zhang W, Perry KW, Wong DT, et al: Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250-262, 2000","DOI":"10.1016\/S0893-133X(00)00119-6"},{"key":"R5211111100","doi-asserted-by":"crossref","unstructured":"McCullough JP: Cognitive-behavioral analysis system of psychotherapy: an interactional treatment approach for dysthymic disorder. Psychiatry 47:234-250, 1984","DOI":"10.1080\/00332747.1984.11024245"},{"key":"R5211111101","doi-asserted-by":"crossref","unstructured":"Keller MB, McCullough JP, Klein DN, et al: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine 342:1462-1470, 2000","DOI":"10.1037\/e492572004-001"}],"container-title":["Psychiatric Services"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ps.52.11.1469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T12:15:55Z","timestamp":1722168955000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ps.52.11.1469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":98,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1176\/appi.ps.52.11.1469"],"URL":"https:\/\/doi.org\/10.1176\/appi.ps.52.11.1469","relation":{},"ISSN":["1075-2730","1557-9700"],"issn-type":[{"value":"1075-2730","type":"print"},{"value":"1557-9700","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}